Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC

Drug resistance is a major obstacle to curative cancer therapies, and increased understanding of the molecular events contributing to resistance would enable better prediction of therapy response, as well as contribute to new targets for combination therapy. Here we have analyzed the early molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou Tran, Yan, Minozada, Rezan, Cao, Xiaofang, Johansson, Henrik J., Branca, Rui M., Seashore-Ludlow, Brinton, Orre, Lukas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Biochemistry and Molecular Biology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261823/
https://www.ncbi.nlm.nih.gov/pubmed/32234966
http://dx.doi.org/10.1074/mcp.RA120.002036
_version_ 1783540564976730112
author Zhou Tran, Yan
Minozada, Rezan
Cao, Xiaofang
Johansson, Henrik J.
Branca, Rui M.
Seashore-Ludlow, Brinton
Orre, Lukas M.
author_facet Zhou Tran, Yan
Minozada, Rezan
Cao, Xiaofang
Johansson, Henrik J.
Branca, Rui M.
Seashore-Ludlow, Brinton
Orre, Lukas M.
author_sort Zhou Tran, Yan
collection PubMed
description Drug resistance is a major obstacle to curative cancer therapies, and increased understanding of the molecular events contributing to resistance would enable better prediction of therapy response, as well as contribute to new targets for combination therapy. Here we have analyzed the early molecular response to epidermal growth factor receptor (EGFR) inhibition using RNA sequencing data covering 13,486 genes and mass spectrometry data covering 10,138 proteins. This analysis revealed a massive response to EGFR inhibition already within the first 24 h, including significant regulation of hundreds of genes known to control downstream signaling, such as transcription factors, kinases, phosphatases and ubiquitin E3-ligases. Importantly, this response included upregulation of key genes in multiple oncogenic signaling pathways that promote proliferation and survival, such as ERBB3, FGFR2, JAK3, and BCL6, indicating an early adaptive response to EGFR inhibition. Using a library of more than 500 approved and experimental compounds in a combination therapy screen, we could show that several kinase inhibitors with targets including JAK3 and FGFR2 increased the response to EGFR inhibitors. Further, we investigated the functional impact of BCL6 upregulation in response to EGFR inhibition using siRNA-based silencing of BCL6. Proteomics profiling revealed that BCL6 inhibited transcription of multiple target genes including p53, resulting in reduced apoptosis which implicates BCL6 upregulation as a new EGFR inhibitor treatment escape mechanism. Finally, we demonstrate that combined treatment targeting both EGFR and BCL6 act synergistically in killing lung cancer cells. In conclusion, or data indicates that multiple different adaptive mechanisms may act in concert to blunt the cellular impact of EGFR inhibition, and we suggest BCL6 as a potential target for EGFR inhibitor-based combination therapy.
format Online
Article
Text
id pubmed-7261823
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The American Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-72618232020-06-09 Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC Zhou Tran, Yan Minozada, Rezan Cao, Xiaofang Johansson, Henrik J. Branca, Rui M. Seashore-Ludlow, Brinton Orre, Lukas M. Mol Cell Proteomics Research Drug resistance is a major obstacle to curative cancer therapies, and increased understanding of the molecular events contributing to resistance would enable better prediction of therapy response, as well as contribute to new targets for combination therapy. Here we have analyzed the early molecular response to epidermal growth factor receptor (EGFR) inhibition using RNA sequencing data covering 13,486 genes and mass spectrometry data covering 10,138 proteins. This analysis revealed a massive response to EGFR inhibition already within the first 24 h, including significant regulation of hundreds of genes known to control downstream signaling, such as transcription factors, kinases, phosphatases and ubiquitin E3-ligases. Importantly, this response included upregulation of key genes in multiple oncogenic signaling pathways that promote proliferation and survival, such as ERBB3, FGFR2, JAK3, and BCL6, indicating an early adaptive response to EGFR inhibition. Using a library of more than 500 approved and experimental compounds in a combination therapy screen, we could show that several kinase inhibitors with targets including JAK3 and FGFR2 increased the response to EGFR inhibitors. Further, we investigated the functional impact of BCL6 upregulation in response to EGFR inhibition using siRNA-based silencing of BCL6. Proteomics profiling revealed that BCL6 inhibited transcription of multiple target genes including p53, resulting in reduced apoptosis which implicates BCL6 upregulation as a new EGFR inhibitor treatment escape mechanism. Finally, we demonstrate that combined treatment targeting both EGFR and BCL6 act synergistically in killing lung cancer cells. In conclusion, or data indicates that multiple different adaptive mechanisms may act in concert to blunt the cellular impact of EGFR inhibition, and we suggest BCL6 as a potential target for EGFR inhibitor-based combination therapy. The American Society for Biochemistry and Molecular Biology 2020-06 2020-03-30 /pmc/articles/PMC7261823/ /pubmed/32234966 http://dx.doi.org/10.1074/mcp.RA120.002036 Text en © 2020 Zhou Tran et al. Author's Choice—Final version open access under the terms of the Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0) .
spellingShingle Research
Zhou Tran, Yan
Minozada, Rezan
Cao, Xiaofang
Johansson, Henrik J.
Branca, Rui M.
Seashore-Ludlow, Brinton
Orre, Lukas M.
Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC
title Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC
title_full Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC
title_fullStr Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC
title_full_unstemmed Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC
title_short Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC
title_sort immediate adaptation analysis implicates bcl6 as an egfr-tki combination therapy target in nsclc
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261823/
https://www.ncbi.nlm.nih.gov/pubmed/32234966
http://dx.doi.org/10.1074/mcp.RA120.002036
work_keys_str_mv AT zhoutranyan immediateadaptationanalysisimplicatesbcl6asanegfrtkicombinationtherapytargetinnsclc
AT minozadarezan immediateadaptationanalysisimplicatesbcl6asanegfrtkicombinationtherapytargetinnsclc
AT caoxiaofang immediateadaptationanalysisimplicatesbcl6asanegfrtkicombinationtherapytargetinnsclc
AT johanssonhenrikj immediateadaptationanalysisimplicatesbcl6asanegfrtkicombinationtherapytargetinnsclc
AT brancaruim immediateadaptationanalysisimplicatesbcl6asanegfrtkicombinationtherapytargetinnsclc
AT seashoreludlowbrinton immediateadaptationanalysisimplicatesbcl6asanegfrtkicombinationtherapytargetinnsclc
AT orrelukasm immediateadaptationanalysisimplicatesbcl6asanegfrtkicombinationtherapytargetinnsclc